HemOnc Today Current Issue
The following articles appeared in the print edition of HemOnc Today.
Table of Contents
- Reimbursement remains ‘difficult issue’ in CAR T-cell therapy rollout
-
- Should patients with ALL undergo HSCT after CAR T-cell therapy? Jonathan M. Gerber, MD, PhD
- A sad week John Sweetenham, MD, FRCP, FACP
- Differences in pharmacology, toxicities key to clinical use of PARP inhibitors Jai N. Patel, PharmD, BCOP, CPP
- Atezolizumab plus bevacizumab extends PFS in metastatic renal cell carcinoma
- Docetaxel improves quality of life for men with prostate cancer
- Persistent opioid use common after lung cancer surgery
- High body fat, even with normal BMI, increases breast cancer risk
- Poor sleep quality associated with higher BMI in children
-
- Rise in Canadian obesity rate may increase country’s cancer burden
- Survey: Fewer than 30% of oncologists ‘very comfortable’ treating severe immune-related adverse events
- Nivolumab demonstrates antitumor activity for HIV-positive Kaposi sarcoma
- Right-sided colorectal tumors have worse outcomes
- Sorafenib plus transarterial chemoembolization improves PFS in unresectable hepatocellular carcinoma
- Patient characteristics correlate with toxicity, response to CAR T-cell therapy in diffuse large B-cell lymphoma
- Brentuximab vedotin combination superior to standard chemotherapy in Hodgkin lymphoma
- Active surveillance shows benefit for rare Hodgkin lymphoma subtype
-
- Combination therapy effective for diffuse large B-cell lymphoma
- Reliance on emergency care for sickle cell disease pain highest among adolescents
- Immunosuppressive therapy leads to transfusion independence for nearly 40% of patients with myelodysplastic syndrome
- Idasanutlin active in refractory polycythemia vera
- Atezolizumab-based triplet effective, but toxic, for follicular lymphoma
- Analysis shows ‘no clear signal’ linking fedratinib to Wernicke’s encephalopathy in myeloproliferative neoplasms
- Talazoparib improves PFS over chemotherapy for patients with BRCA mutations
- Weight loss reduces breast cancer risk for postmenopausal women
-
- Larger margin width reduces local recurrence for early-stage breast cancer
- Myeloablative allogeneic hematopoietic cell transplantation associated with significant cognitive decline
- Dabrafenib plus trametinib first regimen to produce clinical activity in BRAF V600E-mutated anaplastic thyroid cancer
- Physician recommendation drives use of chemoprevention for breast cancer
- Olaparib maintenance therapy prolongs PFS for BRCA-mutated ovarian cancer
- Most older patients with advanced lung cancer receive no therapy
- Family history, disease stage key in determining need for inherited prostate cancer genetic testing
- Failure of lomustine, bevacizumab for progressive glioblastoma likely to cause paradigm shift
-
- Cancer immunotherapy safe for patients with rheumatic diseases
- Patients with glioblastoma fare better when treated at high-volume facilities
- FDA approves Lutathera for gastroenteropancreatic neuroendocrine tumors
- FDA updates Tasigna label to include information on discontinuation
- FDA expands approval of Gilotrif for advanced lung cancer with uncommon EGFR mutations
- FDA grants breakthrough therapy designation to Kisqali for certain premenopausal women with breast cancer
- Pembrolizumab yields positive outcomes in trials for melanoma, NSCLC
- Glowing tumor dye may distinguish tumors from healthy tissue among patients with head, neck cancers
-
- Lymphadenectomy may not add benefit in high-risk renal cell carcinoma
- GC4419 reduces severe oral mucositis in head and neck cancer
- ProscaVax reduces prostate cancer disease progression
- Stem cell transplantation specialist joins Fred Hutchinson Cancer Research Center
- American Institute for Cancer Research funds studies to assess link between lifestyle, malignancy
- ASCO announces new membership roles
- Radiologist joins Fox Chase Cancer Center
- National Academy of Science to honor immunotherapy pioneer
-